Arcturus Therapeutics

#8344

Rank

$216.58M

Marketcap

United States

Country

Leadership team

Mr. Joseph E. Payne M.Sc. (Founder, Pres, CEO & Director)

Dr. Padmanabh Chivukula (Founder, Chief Scientific Officer, COO & Sec.)

Mr. Andrew H. Sassine MBA (CFO & Director)

Products/ Services

Biotechnology, Genetics, Health Care, Medical, Therapeutics

Number of Employees

100 - 500

Headquarters

San Diego, California, United States

Established

2013

Company Registration

SEC CIK number: 0001768224

Revenue

20M - 100M

Traded as

ARCT

Social Media

URL

https://arcturusrx.com

Overview

Location

Recognition and Award

References

Summary

Arcturus Therapeutics Holdings Inc., an RNA medicines company, focuses on the development of vaccines for infectious, and liver and respiratory rare diseases in the United States. The company's development programs comprise LUNAR-OTC development program for ornithine transcarbamylase (OTC) deficiency; and LUNAR-CF program for cystic fibrosis lung disease caused by mutations in cystic fibrosis transmembrane conductance regulator (CFTR) gene, as well as vaccine programs include LUNAR-COV19 and LUNAR-FLU. It has collaboration partnerships with Vinbiocare Biotechnology Joint Stock Company for the manufacture of COVID-19 vaccines; Janssen Pharmaceuticals, Inc. to develop nucleic acid-based therapeutic candidates for the treatment of hepatitis B virus; Ultragenyx Pharmaceutical, Inc. to develop mRNA therapeutic candidates for rare disease targets; CureVac AG to develop mRNA therapeutic and vaccine candidates for various indications; Singapore Economic Development Board and Duke-NUS Medical School to develop LUNAR-COV19 vaccine; and Millennium Pharmaceuticals, Inc. to discover siRNA medicines for the treatment of non-alcoholic steatohepatitis. The company was founded in 2013 and is headquartered in San Diego, California.

History

Founded in 2013, Arcturus Therapeutics has rapidly grown into a leading company in the RNA medicines space. Arcturus has established strong collaborations with Janssen Pharmaceutical Companies of Johnson & Johnson and Ultragenyx Pharmaceutical Inc. and has 25+ issued patents and more than 50 patent applications pending covering the key elements of its RNA medicines platform.

Mission

Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company.

Vision

Our vision is to be a major player in the global effort to develop safe and effective RNA medicines for a better future for both patients and medical professionals.

Key Team

Mr. Lance Kurata (Chief Legal Officer)

Dr. Steven George Hughes M.B.A., M.D. (Strategic Clinical Advisor & Member of Scientific Advisory Board)

Mr. Keith C. Kummerfeld CPA (VP of Fin. & Corp. Controller)

Dr. Dushyant B. Varshney Ph.D. (Exec. VP & Chief Technology Officer)

Mr. Deepankar Roy (Sr. Director of Investor Relations)

Kyle Gutstadt (Sr. Analyst of Investor & PR)

Mr. Kevin T. Skol (Sr. VP of Bus. Devel. & Alliance Management)

Recognition and Awards

Arcturus is the proud recipient of the 2017 Longevity Leadership Award, the 2016 Start-up Innovation Award for RNA Therapeutics, the 2014 CTI-Lifesciences Pitch Award and the 2013 Cambridge Enterprise Grand Challenges Award.